发明公开
EP1586324A1 OPHTHALMIC THERAPEUTIC COMPOSITION
有权
Verwendung vom Pentapeptid PHSRN在opthalmischen Formulierungen
- 专利标题： OPHTHALMIC THERAPEUTIC COMPOSITION
- 专利标题（中）： Verwendung vom Pentapeptid PHSRN在opthalmischen Formulierungen
-
申请号： EP03786242.2申请日： 2003-12-24
-
公开(公告)号： EP1586324A1公开(公告)日： 2005-10-19
- 发明人: Nishida, Teruo , Uetake, Y., Nihon Tenganyaku Kenkyusho Co., Ltd. , Iwata, Hiroaki
- 申请人： Nihon Tenganyaku Kenkyusyo Co., Ltd. , Nishida, Teruo
- 申请人地址： 76, Nishisakuracho, Minami-ku Nagoya-shi, Aichi 457-0039 JP
- 专利权人： Nihon Tenganyaku Kenkyusyo Co., Ltd.,Nishida, Teruo
- 当前专利权人： Nihon Tenganyaku Kenkyusyo Co., Ltd.,Nishida, Teruo
- 当前专利权人地址： 76, Nishisakuracho, Minami-ku Nagoya-shi, Aichi 457-0039 JP
- 代理机构： Grünberg, Thomas
- 优先权： JP2002381131 20021227
- 国际公布： WO2004060385 20040722
- 主分类号： A61K38/00
- IPC分类号： A61K38/00 ; A61K9/08 ; A61P27/02 ; A61P43/00
摘要：
An object is to find the minimum activity expression site of fibronectin, clarify the actions of this minimum unit in relation to ophthalmological fields, and provide a ophthalmological composition having this minimum unit as an effective component. This invention provides an ophthalmological composition, in particular, a corneal disorder treatment agent containing the peptide, PHSRN (Pro-His-Ser-Arg-Asn), or Ac-Pro-His-Ser-Arg-Asn-NH 2 , which is a derivative thereof, or a salt thereof that is allowable as a medical drug as an effective component. The preferred dosage form is an ophthalmic formulation.
公开/授权文献
- EP1586324B1 Use of the pentapeptide PHSRN in ophthalmic formulations 公开/授权日：2014-04-16
信息查询
IPC分类:
